Predictors of surgical outcome and early criteria of remission in acromegaly
- 34 Downloads
Transsphenoidal surgery (TSS) is the cornerstone of acromegaly treatment, however there are no robust predictors of surgical outcome and remission can only be defined three months after surgery.
To analyze if biochemical, demographical, radiological, and immunohistochemical characteristics are predictors of surgical remission and investigate if immediate postoperative GH and IGF-I levels can help defining remission earlier.
Consecutive acromegaly patients submitted to TSS between 2013-2016 were evaluated. Remission criteria was defined as normal IGF-I and GH <1 mcg/L three months after surgery. Data of age, sex, GH and IGF-I levels, tumor volume, cavernous sinus invasion, T2-weighted signal, Ki-67, and granulation pattern were correlated with remission status. GH and IGF-I levels at 24, 48 h, and one week postoperative were evaluated as early criteria of remission.
Sixty-nine patients were included (84% macroadenomas) and surgical remission was achieved in 45%. No difference between cured and not cured patients concerning age, gender, preoperative GH or IGF-I levels, tumor volume, T2-weighted signal, Ki-67 and tumor granularity was observed. Remission was obtained in 20 of 36 (56%) of the non-invasive tumors, and in 3 of 16 (19%) of the invasive tumors (p = 0.017). A GH <1.57 mcg/L 48 h after surgery was able to predict remission with 93% sensitivity and 86% specificity and an IGF-I < 231% ULNR one week after surgery predicted remission with 86% sensitivity and 93% specificity.
Cavernous sinus invasion is the only preoperative predictor of surgical remission. GH at 48 h and IGF-I one week after surgery can define earlier not cured patients.
Key wordsAcromegaly Surgery Predictors of surgical outcome Early criteria of remission
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.S.M.S. Michael Buchfelder, The surgical treatment of acromegaly. Pituitary (2016). https://doi.org/10.1007/s11102-016-0765-7
- 3.J.A. Jane Jr., R.M. Starke, M.A. Elzoghby, D.L. Reames, S.C. Payne, M.O. Thorner, J.C. Marshall, E.R. Laws Jr., M.L. Vance, Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J. Clin. Endocrinol. Metab. 96(9), 2732–2740 (2011). https://doi.org/10.1210/jc.2011-0554 CrossRefPubMedGoogle Scholar
- 4.P. Petrossians, L. Borges-Martins, C. Espinoza, A. Daly, D. Betea, H. Valdes-Socin, A. Stevenaert, P. Chanson, A. Beckers, Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152(1), 61–66 (2005)CrossRefPubMedGoogle Scholar
- 6.H. Sun, J. Brzana, C.G. Yedinak, S.H. Gultekin, J.B. Delashaw, M. Fleseriu, Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. Journal of neurological surgery. Part B. Skull Base 75(1), 47–52 (2014). https://doi.org/10.1055/s-0033-1354578 PubMedGoogle Scholar
- 7.K. Kiseljak-Vassiliades, N.E. Carlson, M.T. Borges, B.K. Kleinschmidt-DeMasters, K.O. Lillehei, J.M. Kerr, M.E. Wierman, Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1), 231–241 (2015). https://doi.org/10.1007/s12020-014-0383-y CrossRefPubMedGoogle Scholar
- 8.P.R. Mazal, T. Czech, R. Sedivy, M. Aichholzer, J. Wanschitz, N. Klupp, H. Budka, Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin. Neuropathol. 20(4), 163–171 (2001)PubMedGoogle Scholar
- 9.Y. Bakhtiar, H. Hirano, K. Arita, S. Yunoue, S. Fujio, A. Tominaga, T. Sakoguchi, K. Sugiyama, K. Kurisu, J. Yasufuku-Takano, K. Takano, Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163(4), 531–539 (2010). https://doi.org/10.1530/EJE-10-0586 CrossRefPubMedGoogle Scholar
- 11.V. Briceno, H.A. Zaidi, J.A. Doucette, K.B. Onomichi, A. Alreshidi, R.A. Mekary, T.R. Smith, Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol. Res 39(5), 387–398 (2017). https://doi.org/10.1080/01616412.2017.1296653 CrossRefPubMedGoogle Scholar
- 12.C.C. van Bunderen, N.C. van Varsseveld, J.C. Baayen, W.R. van Furth, E.S. Aliaga, M.J. Hazewinkel, C.B. Majoie, N.J. Freling, P. Lips, E. Fliers, P.H. Bisschop, M.L. Drent, Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: patient and tumor characteristics evaluated by magnetic resonance imaging. Pituitary 16(2), 158–167 (2013). https://doi.org/10.1007/s11102-012-0395-7 CrossRefPubMedGoogle Scholar
- 13.A. Heck, K.E. Emblem, O. Casar-Borota, J. Bollerslev, G. Ringstad, Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2), 333–343 (2016). https://doi.org/10.1007/s12020-015-0766-8 CrossRefPubMedGoogle Scholar
- 14.A. Heck, G. Ringstad, S.L. Fougner, O. Casar-Borota, T. Nome, J. Ramm-Pettersen, J. Bollerslev, Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. 77(1), 72–78 (2012). https://doi.org/10.1111/j.1365-2265.2011.04286.x CrossRefGoogle Scholar
- 15.M. Shen, Q. Zhang, W. Liu, M. Wang, J. Zhu, Z. Ma, W. He, S. Li, X. Shou, Y. Li, Z. Zhang, H. Ye, M. He, B. Lu, Z. Yao, Y. Lu, N. Qiao, Z. Ye, Y. Zhang, Y. Yang, Y. Zhao, Y. Wang, Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 58(11), 1057–1065 (2016). https://doi.org/10.1007/s00234-016-1728-4 CrossRefPubMedGoogle Scholar
- 17.A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82–91 (2008). https://doi.org/10.1007/s12022-008-9029-z CrossRefPubMedGoogle Scholar
- 18.H. Nishioka, N. Fukuhara, K. Horiguchi, S. Yamada, Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes. J. Neurosurg. 121(3), 505–510 (2014). https://doi.org/10.3171/2014.3.JNS132214 CrossRefPubMedGoogle Scholar
- 19.A.E. Yildirim, M. Sahinoglu, D. Divanlioglu, F. Alagoz, A.G. Gurcay, E. Daglioglu, H.O. Okay, A.D. Belen, Endoscopic endonasal transsphenoidal treatment for acromegaly: 2010 consensus criteria for remission and predictors of outcomes. Turk. Neurosurg. 24(6), 906–912 (2014). https://doi.org/10.5137/1019-5149.JTN.11288-14.1 PubMedGoogle Scholar
- 21.A. Abosch, J.B. Tyrrell, K.R. Lamborn, L.T. Hannegan, C.B. Applebury, C.B. Wilson, Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 83(10), 3411–3418 (1998). https://doi.org/10.1210/jcem.83.10.5111 CrossRefPubMedGoogle Scholar
- 22.D.B. Hazer, S. Isik, D. Berker, S. Guler, A. Gurlek, T. Yucel, M. Berker, Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. J. Neurosurg. 119(6), 1467–1477 (2013). https://doi.org/10.3171/2013.8.JNS13224 CrossRefPubMedGoogle Scholar
- 23.R.M. Starke, D.M. Raper, S.C. Payne, M.L. Vance, E.H. Oldfield, J.A. Jane Jr., Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J. Clin. Endocrinol. Metab. 98(8), 3190–3198 (2013). https://doi.org/10.1210/jc.2013-1036 CrossRefPubMedGoogle Scholar
- 25.J.A. Gondim, J.P. Almeida, L.A. de Albuquerque, E. Gomes, M. Schops, T. Ferraz, Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg. Focus 29(4), E7 (2010). https://doi.org/10.3171/2010.7.FOCUS10167 CrossRefPubMedGoogle Scholar
- 26.R. Attanasio, M. Montini, M. Valota, L. Cortesi, R. Barbo, F. Biroli, G. Tonnarelli, M. Albizzi, R.M. Testa, G. Pagani, An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy. Pituitary 11(1), 1–11 (2008). https://doi.org/10.1007/s11102-007-0059-1 CrossRefPubMedGoogle Scholar
- 27.I. Potorac, P. Petrossians, A.F. Daly, F. Schillo, C. Ben Slama, S. Nagi, M. Sahnoun, T. Brue, N. Girard, P. Chanson, G. Nasser, P. Caron, F. Bonneville, G. Raverot, V. Lapras, F. Cotton, B. Delemer, B. Higel, A. Boulin, S. Gaillard, F. Luca, B. Goichot, J.L. Dietemann, A. Beckers, J.F. Bonneville, Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr. Relat. Cancer 22(2), 169–177 (2015). https://doi.org/10.1530/ERC-14-0305 CrossRefPubMedGoogle Scholar
- 28.A. Hagiwara, Y. Inoue, K. Wakasa, T. Haba, T. Tashiro, T. Miyamoto, Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2), 533–538 (2003). https://doi.org/10.1148/radiol.2282020695 CrossRefPubMedGoogle Scholar
- 29.M. Puig-Domingo, E. Resmini, B. Gomez-Anson, J. Nicolau, M. Mora, E. Palomera, C. Marti, I. Halperin, S.M. Webb, Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J. Clin. Endocrinol. Metab. 95(11), 4973–4978 (2010). https://doi.org/10.1210/jc.2010-0573 CrossRefPubMedGoogle Scholar
- 30.H. Babu, A. Ortega, M. Nuno, A. Dehghan, A. Schweitzer, H.V. Bonert, J.D. Carmichael, O. Cooper, S. Melmed, A.N. Mamelak, Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. Neurosurgery 81(2), 357–366 (2017). https://doi.org/10.1093/neuros/nyx020 CrossRefPubMedGoogle Scholar
- 31.R.A. Feelders, M. Bidlingmaier, C.J. Strasburger, J.A. Janssen, P. Uitterlinden, L.J. Hofland, S.W. Lamberts, A.J. van der Lely, W.W. de Herder, Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J. Clin. Endocrinol. Metab. 90(12), 6480–6489 (2005). https://doi.org/10.1210/jc.2005-0901 CrossRefPubMedGoogle Scholar
- 32.P. Dutta, M. Korbonits, N. Sachdeva, P. Gupta, A. Srinivasan, J.S. Devgun, A. Bajaj, K.K. Mukherjee, Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly? Neurol. India 64(2), 252–258 (2016). https://doi.org/10.4103/0028-3886.177622 CrossRefPubMedGoogle Scholar
- 35.E.H. Kim, M.C. Oh, E.J. Lee, S.H. Kim, Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. Neurosurgery 70(5), 1106–1113 (2012). https://doi.org/10.1227/NEU.0b013e31823f5c16. discussion 1113CrossRefPubMedGoogle Scholar